Page 1664 - Williams Hematology ( PDFDrive )

1638 Part XI: Malignant Lymphoid Diseases Chapter 98: Diffuse Large B-Cell Lymphoma and Related Diseases 1639

75. Kaiser U, Uebelacker I, Abel U, et al: Randomized study to evaluate the use of high-dose 105. Zucca E, Conconi A, Mughal TI, et al: Patterns of outcome and prognostic factors in
therapy as part of primary treatment for “aggressive” lymphoma. J Clin Oncol 20:22, primary large-cell lymphoma of the testis in a survey by the International Extranodal
2002. Lymphoma Study Group. J Clin Oncol 21:1, 2003.
76. Stiff P, Unger J, Cook J, et al: Autologous transplantation as consolidation for aggressive 106. Gundrum JD, Mathiason MA, Derek BM, et al: Primary testicular diffuse large B-cell
non-Hodgkin’s lymphoma. N Engl J Med 369:18, 2013. lymphoma: A population-based study on the incidence, natural history, and survival
77. Greb A, Bohlius J, Schiefer D, et al: High-dose chemotherapy with autologous stem cell comparison with primary nodal counterpart before and after the introduction of ritux-
transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) imab. J Clin Oncol 27:5227, 2009.
in adults. Cochrane Database Syst Rev 1:CD004024, 2008. 107. Pingali S, Go RS, Gundrum JD, et al: Adult testicular lymphoma in the United States
78. Maurer M, Ghesquieres H, Jais J: Event-free survival at 24 months is a robust end point (1985–2004): Analysis of 3,669 cases from the National Cancer Data Base (NCDB).
for disease-related outcome in diffuse large B-cell lymphoma treated with immunoche- J Clin Oncol 26(15S):19503, 2008.
motherapy. J Clin Oncol 32:10, 2014. 108. Fonseca R, Habermann TM, Colgan JP, et al: Testicular lymphoma is associated with a
79. Schmoll H: Review of etoposide single-agent activity. Cancer Treat Rev 9 Suppl:21, high incidence of extranodal recurrence. Cancer 88:1, 2000.
1982. 109. Visco C, Medeiros LJ, Mesina OM, et al: Non-Hodgkin’s lymphoma affecting the testis:
80. Shipp MA, Takvorian RC, Canellos GP: High-dose cytosine arabinoside. Active agent Is it curable with doxorubicin-based therapy? Clin Lymphoma 2:1, 2001.
in treatment of non-Hodgkin’s lymphoma. Am J Med 77:5, 1984. 110. Pentheroudakis G, Pavlidis N: Cancer and pregnancy: Poena magna, not anymore.
81. Bajetta E, Buzzoni R, Valagussa P, Bonadonna G: Mitoxantrone: An active agent in Eur J Cancer 42:2, 2006.
refractory non-Hodgkin’s lymphomas. Am J Clin Oncol 11:2, 1988. 111. Pereg D, Koren G, Lishner M: Cancer in pregnancy: Gaps, challenges and solutions.
82. Wiernik PH, Lossos IS, Tuscano JM, et al: Lenalidomide monotherapy in relapsed or Cancer Treat Rev 34:4, 2008.
refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 26:30, 2008. 112. Pereg D, Koren G, Lishner M: The treatment of Hodgkin’s and non-Hodgkin’s
83. Rizzieri DA, Sand GJ, McGaughey D, et al: Low-dose weekly paclitaxel for recurrent or lymphoma in pregnancy. Haematologica 92:9, 2007.
refractory aggressive non-Hodgkin lymphoma. Cancer 100:11, 2004. 113. Aviles A, Diaz-Maqueo JC, Torras V, et al: Non-Hodgkin’s lymphomas and pregnancy:
84. Kewalramani T, Zelenetz AD, Nimer SD, et al: Rituximab and ICE as second-line Presentation of 16 cases. Gynecol Oncol 37:3, 1990.
therapy before autologous stem cell transplantation for relapsed or primary refractory 114. Evens AM, Advani R, Press OW, et al: Lymphoma occurring during pregnancy: Ante-
diffuse large B-cell lymphoma. Blood 103:10, 2004. natal therapy, complications, and maternal survival in a multicenter analysis. J Clin
85. Velasquez WS, McLaughlin P, Tucker S, et al: ESHAP—An effective chemotherapy regi- Oncol 31:32, 2013.
men in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 12:6, 115. Resnik R: Cancer during pregnancy. N Engl J Med 341:2, 1999.
1994. 116. van Besien K, Kelta M, Bahaguna P: Primary mediastinal B-cell lymphoma: A review of
86. Gisselbrecht C, Glass B, Mounier N, et al: Salvage regimens with autologous transplan- pathology and management. J Clin Oncol 19:6, 2001.
tation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:27, 2010. 117. Savage KJ, Monti S, Kutok JL, et al: The molecular signature of mediastinal large B-cell
87. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation lymphoma differs from that of other diffuse large B-cell lymphomas and shares features
as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non- with classical Hodgkin lymphoma. Blood 102:12, 2003.
Hodgkin’s lymphoma. N Engl J Med 333:23, 1995. 118. Perrone T, Frizzera G, Rosai J: Mediastinal diffuse large-cell lymphoma with sclerosis.
88. Chopra R, Goldstone AH, Pearce R, et al: Autologous versus allogeneic bone marrow A clinicopathologic study of 60 cases. Am J Surg Pathol 10:3, 1986.
transplantation for non-Hodgkin’s lymphoma: A case-controlled analysis of the Euro- 119. Zinzani PL, Martelli M, Bertini M, et al: Induction chemotherapy strategies for primary
pean Bone Marrow Transplant Group Registry data. J Clin Oncol 10:11, 1992. mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study
89. Rezvani AR, Norasetthada L, Gooley T, et al: Non-myeloablative allogeneic haemato- on 426 previously untreated patients. Haematologica 87:12, 2002.
poietic cell transplantation for relapsed diffuse large B-cell lymphoma: A multicentre 120. Todeschini G, Secchi S, Morra E, et al: Primary mediastinal large B-cell lymphoma
experience. Br J Haematol 143:3, 2008. (PMLBCL): Long-term results from a retrospective multicentre Italian experi-
90. Thomson KJ, Morris EC, Bloor A, et al: Favorable long-term survival after reduced- ence in 138 patients treated with CHOP or MACOP-B/VACOP-B: Br J Cancer 90:2,
intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin’s 2004.
lymphoma. J Clin Oncol 27:3, 2009. 121. Dunleavy K, Pittaluga S, Maeda L, et al: Dose-adjusted EPOCH-rituximab therapy in
91. Krishnan A, Nademanee A, Fung HC, et al: Phase II trial of a transplantation regimen primary mediastinal B-cell lymphoma. N Engl J Med 368:15, 2013.
of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non- 122. Katzenstein AL, Carrington CB, Liebow AA: Lymphomatoid granulomatosis: A clini-
Hodgkin’s lymphoma. J Clin Oncol 26:1, 2008. copathologic study of 152 cases. Cancer 43:1, 1979.
92. Vose JM, Bierman PJ, Enke C, et al: Phase I trial of iodine-131 tositumomab with 123. Gitelson E, Al-Saleem T, Smith MR: Review: Lymphomatoid granulomatosis: Chal-
high-dose chemotherapy and autologous stem-cell transplantation for relapsed non- lenges in diagnosis and treatment. Clin Adv Hematol Oncol 7:1, 2009.
Hodgkin’s lymphoma. J Clin Oncol 23:3, 2005. 124. Dunleavy K, Janik J, Cohen J, et al: 16. Clinical-pathological correlations: 079 Study of
93. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non- the treatment and biology of lymphomatoid granulomatosis (LYG); a rare EBV lymph-
Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329:14, 1993. oproliferative disorder. Ann Oncol 16:v59, 2005.
94. A clinical evaluation of the International Lymphoma Study Group classification of non- 125. Ferreri AJ, Campo E, Seymour JF, et al: Intravascular lymphoma: Clinical presentation,
Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood natural history, management and prognostic factors in a series of 38 cases, with special
89:11, 1997. emphasis on the “cutaneous variant.” Br J Haematol 127:2, 2004.
95. Zhou Z, Sehn L, Rademaker A, et al: An enhanced international prognostic index 126. Ferreri AJ, Dognini GP, Campo E, et al: Variations in clinical presentation, frequency
(NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in
era. Blood 123:6, 2014. different geographical regions. Haematologica 92:4, 2007.
96. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular clas- 127. Murase T, Nakamura S: An Asian variant of intravascular lymphomatosis: An updated
sification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue review of malignant histiocytosis-like B-cell lymphoma. Leuk Lymphoma 33:5, 1999.
microarray. Blood 103:1, 2004. 128. Murase T, Nakamura S, Kawauchi K, et al: An Asian variant of intravascular large B-cell
97. Shipp MA, Ross KN, Tamayo P, et al: Diffuse large B-cell lymphoma outcome predic- lymphoma: Clinical, pathological and cytogenetic approaches to diffuse large B-cell
tion by gene-expression profiling and supervised machine learning. Nat Med 8:1, 2002. lymphoma associated with haemophagocytic syndrome. Br J Haematol 111:3, 2000.
98. Lossos IS, Czerwinski DK, Alizadeh AA, et al: Prediction of survival in diffuse large-B- 129. Shimazaki C, Inaba T, Nakagawa M: B-cell lymphoma-associated hemophagocytic syn-
cell lymphoma based on the expression of six genes. N Engl J Med 350:18, 2004. drome. Leuk Lymphoma 38:1, 2000.
99. Swan F Jr, Velasquez WS, Tucker S, et al: A new serologic staging system for large-cell 130. Ponzoni M, Ferreri AJ, Campo E, et al: Definition, diagnosis, and management of intra-
lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J vascular large B-cell lymphoma: Proposals and perspectives from an international con-
Clin Oncol 7:10, 1989. sensus meeting. J Clin Oncol 25:21, 2007.
100. Savage K, Johnson N, Ben-Neriah S, et al: MYC gene rearrangements are associated 131. Ferreri AJ, Dognini GP, Govi S, et al: Can rituximab change the usually dismal progno-
with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP sis of patients with intravascular large B-cell lymphoma? J Clin Oncol 26:31, 2008.
chemotherapy. Blood 114:17, 2009. 132. Shimada K, Matsue K, Yamamoto K, et al: Retrospective analysis of intravascular large
101. Kluk M, Chapuy B, Sinha P, et al: Immunohistochemical detection of MYC-driven dif- B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the
fuse large B-cell lymphomas. PloS One 7:4, 2012. IVL study group in Japan. J Clin Oncol 26:19, 2008.
102. Johnson N, Slack G, Savage K, et al: Concurrent expression of MYC and BCL2 in diffuse 133. Oton AB, Wang H, Leleu X, et al: Clinical and pathological prognostic markers for
large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, survival in adult patients with post-transplant lymphoproliferative disorders in solid
vincristine, and prednisone. J Clin Oncol 30:28, 2013. transplant. Leuk Lymphoma 49:9, 2008.
103. Buchmann I, Reinhardt M, Elsner K, et al: 2-(fluorine-18)fluoro-2-deoxy-d-glucose 134. Adami J, Gabel H, Lindelof B, et al: Cancer risk following organ transplantation:
positron emission tomography in the detection and staging of malignant lymphoma. A A nationwide cohort study in Sweden. Br J Cancer 89:7, 2003.
bicenter trial. Cancer 91:5, 2001. 135. Tsao L, Hsi ED: The clinicopathologic spectrum of posttransplantation lymphoprolifer-
104. Spaepen K, Stroobants S, Dupont P, et al: Prognostic value of positron emission ative disorders. Arch Pathol Lab Med 131:8, 2007.
tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line 136. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA: Post-transplant lymphoprolifera-
chemotherapy in non-Hodgkin’s lymphoma: Is [18F]FDG-PET a valid alternative to tive disorder in renal allograft recipients. Clinical experience and risk factor analysis in
conventional diagnostic methods? J Clin Oncol 19:2, 2001. a single center. Transplantation 56:1, 1993.

Kaushansky_chapter 98_p1625-1640.indd 1639 9/18/15 11:42 PM